Research on the role of circulating tumour DNA (ctDNA) in metastatic castration-resistant prostate cancer (mCRPC) gains momentum, as a new study finds ctDNA assessment promising in the monitoring and prognosis of mCRPC and in identifying new therapeutic targets for the disease.
A recent study presented at the ASCO Genitourinary Cancers Symposium 2017 held in Orlando, Florida, US showed that antibiotic use in patients with metastatic renal cell carcinoma (mRCC) may dampen the efficacy of PD-1/PD-L1 inhibitors.
Patients with castration-resistant prostate cancer (CRPC) may be able to reduce treatment cost by taking low-dose abiraterone acetate with a low-fat breakfast as a study shows noninferiority of the regimen compared with standard dosing on an empty stomach.
Some patients with metastatic renal cell carcinoma (mRCC) who respond to PD-1/PD-L1 immunotherapy can have persistent clinical benefit after treatment discontinuation due to immune-related adverse events.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Doctor - Malaysia digital copy today!
Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.
The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.